Find Clinical Trial

Home » Find Clinical Trials » A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

← Back

Study Phase	Phase 1

Therapeutic Area	Cancers

Indication	Blood cancer

Sponsor	Institut de Recherches Internationales Servier

Active substance/ Medical device	AG-120

Active Substance Code	AG-120

Protocol Code	AG120-C-001

EudraCT Code	2014-000480-40

NCT Code	NCT02074839

Documents and links

Results are not yet available.

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.